Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Synergistic Leukaemia Cell Death Induced with PARP and TiP60 Inhibitors Is a Prospective Therapeutic Strategy for AML

Tae Ju Park, Laura Monaghan, Mhairi Copland, Xu Huang, Helen Wheadon, Heather G Jørgensen

Blood (2022) 140 (Supplement 1): 13001–13002.

https://doi.org/10.1182/blood-2022-166103

Published: 2022

Journal Articles

NFATC2 regulates Targets of MYC Signaling in MLL-AF9 AML

Shaun David Patterson, Matthew E Massett, Helen Wheadon, Xu Huang, Heather G Jørgensen, Alison M Michie

Blood (2021) 138 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2021-151388

Published: 2021

Journal Articles

Uncoupling p53 from an Embryonic Regulome Exhausts Quiescent CML Stem Cells through Inhibition of a HIF1alpha Molecular Program

Mary T Scott, Wei Liu, Rebecca Mitchell, Cassie Clarke, Hassan Almasoudi, Felix Warren, Ross Kinstrie, Karen Dunn, John Pritchard, Mark E Drotar, Alison M Michie, Heather G Jørgensen, Brian Higgins, Mhairi Copland, David Vetrie

Blood (2021) 138 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2021-150372

Published: 2021

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Anuradha Tarafdar, Lisa E. M. Hopcroft, Paolo Gallipoli, Francesca Pellicano, Jennifer Cassels, Alan Hair, Koorosh Korfi, Heather G. Jørgensen, David Vetrie, Tessa L. Holyoake, Alison M. Michie

Blood (2017) 129 (2): 199–208.

https://doi.org/10.1182/blood-2016-09-742049

Published: 2017

Includes: Supplemental data

Journal Articles

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Bin Zhang, Su Chu, Puneet Agarwal, Victoria L. Campbell, Lisa Hopcroft, Heather G. Jørgensen, Allen Lin, Karl Gaal, Tessa L. Holyoake, Ravi Bhatia

Blood (2016) 128 (23): 2671–2682.

https://doi.org/10.1182/blood-2015-11-679928

Published: 2016

Journal Articles

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34 + cells in vitro and in vivo

Paolo Gallipoli, Amy Cook, Susan Rhodes, Lisa Hopcroft, Helen Wheadon, Anthony D. Whetton, Heather G. Jørgensen, Ravi Bhatia, Tessa L. Holyoake

Blood (2014) 124 (9): 1492–1501.

https://doi.org/10.1182/blood-2013-12-545640

Published: 2014

Includes: Supplemental data

Journal Articles

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

Paolo Gallipoli, Francesca Pellicano, Heather Morrison, Kamilla Laidlaw, Elaine K. Allan, Ravi Bhatia, Mhairi Copland, Heather G. Jørgensen, Tessa L. Holyoake

Blood (2013) 122 (19): 3335–3339.

https://doi.org/10.1182/blood-2013-02-485607

Published: 2013

Includes: Supplemental data

Journal Articles

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells

Nicholas B. Heaney, Francesca Pellicano, Bin Zhang, Lisa Crawford, Su Chu, Syed M. A. Kazmi, Elaine K. Allan, Heather G. Jorgensen, Alexandra E. Irvine, Ravi Bhatia, Tessa L. Holyoake

Blood (2010) 115 (11): 2241–2250.

https://doi.org/10.1182/blood-2008-06-164582

Published: 2010

Includes: Supplemental data

Journal Articles

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34 + 38 − cells, through activation of protein kinase Cβ

Francesca Pellicano, Mhairi Copland, Heather G. Jorgensen, Joanne Mountford, Brian Leber, Tessa L. Holyoake

Blood (2009) 114 (19): 4186–4196.

https://doi.org/10.1182/blood-2009-05-219550

Published: 2009

Includes: Supplemental data

Journal Articles

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Joanne Mountford, PhD, Andrea Davies, Niove E Jordanides, Athina Giannoudis, Claire M Lucas, Sophia Hatziieremia, Robert J Harris, Heather G Jorgensen, Munir Pirmohamed, Tessa L Holyoake, Richard E Clark

Blood (2008) 112 (11): 3205.

https://doi.org/10.1182/blood.V112.11.3205.3205

Published: 2008

Journal Articles

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Gordon R. Strathdee, Tessa L. Holyoake, Alyson Sim, Anton Parker, David G. Oscier, Junia V. Melo, Stefan Meyer, Tim Eden, Anne M. Dickinson, Joanne Mountford, Heather G. Jorgensen, Richard Soutar, Robert Brown

Blood (2007) 110 (11): 2641.

https://doi.org/10.1182/blood.V110.11.2641.2641

Published: 2007

Journal Articles

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells

Heather G. Jørgensen, Elaine K. Allan, Niove E. Jordanides, Joanne C. Mountford, Tessa L. Holyoake

Blood (2007) 109 (9): 4016–4019.

https://doi.org/10.1182/blood-2006-11-057521

Published: 2007

Journal Articles

Functional ABCG2 is overexpressed on primary CML CD34 + cells and is inhibited by imatinib mesylate

Niove E. Jordanides, Heather G. Jorgensen, Tessa L. Holyoake, Joanne C. Mountford

Blood (2006) 108 (4): 1370–1373.

https://doi.org/10.1182/blood-2006-02-003145

Published: 2006

Journal Articles

Punish the parent not the progeny

Lucy J. Elrick, Heather G. Jorgensen, Joanne C. Mountford, Tessa L. Holyoake

Blood (2005) 105 (5): 1862–1866.

https://doi.org/10.1182/blood-2004-08-3373

Published: 2005

Journal Articles

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD, MRPharmS, Elaine K. Allan, BSc (Hons), Joanne C. Mountford, PhD, Linda Richmond, BSc(Hons), Moira A. Elliott, PhD, MRPharmS, Tessa L. Holyoake, MD, PhD

Blood (2004) 104 (11): 1997.

https://doi.org/10.1182/blood.V104.11.1997.1997

Published: 2004

Journal Articles

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD MRPharmS, Mhairi Copland, MD, Elaine K. Allan, BSc(Hons), Allen C. Eaves, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 2941.

https://doi.org/10.1182/blood.V104.11.2941.2941

Published: 2004

Journal Articles

α 1 -Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Heather G. Jørgensen, Moira A. Elliott, Elaine K. Allan, Christine E. Carr, Tessa L. Holyoake, Kevin D. Smith

Blood (2002) 99 (2): 713–715.

https://doi.org/10.1182/blood.V99.2.713

Published: 2002

Journal Articles

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

Susan M. Graham, Heather G. Jørgensen, Elaine Allan, Charlie Pearson, Michael J. Alcorn, Linda Richmond, Tessa L. Holyoake

Blood (2002) 99 (1): 319–325.

https://doi.org/10.1182/blood.V99.1.319

Published: 2002

Journal Articles

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

Tessa L. Holyoake, Xiaoyan Jiang, Heather G. Jorgensen, Susan Graham, Michael J. Alcorn, Chris Laird, Allen C. Eaves, Connie J. Eaves

Blood (2001) 97 (3): 720–728.

https://doi.org/10.1182/blood.V97.3.720

Published: 2001

NARROW

Synergistic Leukaemia Cell Death Induced with PARP and TiP60 Inhibitors Is a Prospective Therapeutic Strategy for AML

NFATC2 regulates Targets of MYC Signaling in MLL-AF9 AML

Uncoupling p53 from an Embryonic Regulome Exhausts Quiescent CML Stem Cells through Inhibition of a HIF1alpha Molecular Program

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34 + cells in vitro and in vivo

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34 + 38 − cells, through activation of protein kinase Cβ

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells

Functional ABCG2 is overexpressed on primary CML CD34 + cells and is inhibited by imatinib mesylate

Punish the parent not the progeny

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

α 1 -Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only